Please ensure Javascript is enabled for purposes of website accessibility

6 Million Americans Are Rooting for Monday's Big Stock Market Winner

By Dan Caplinger - Updated Jun 7, 2021 at 4:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not just about money. This company could change millions of lives for the better.

It's not every day that a news event involving the stock market has the potential to change the lives of millions of people for the better. But that's what happened today, and although the decision involves some controversy, the latest approval from the U.S. Food and Drug Administration paves the way for a potential breakthrough for the more than 6 million Americans who suffer from a terrible and debilitating illness.

To be clear, the entire stock market didn't celebrate the news. The Dow Jones Industrial Average and S&P 500 were both down on the day, although gains for the Nasdaq Composite were nice to see.

Index

Percentage Change

Point Change

Dow Jones Industrial Average (^DJI 0.45%)

(0.36%)

(126)

S&P 500 (^GSPC 0.40%)

(0.08%)

(3)

Nasdaq Composite (^IXIC 0.00%)

0.49%

67

Data source: Yahoo! Finance.

Indeed, the Nasdaq's gain came in part from the performance of the high-flying stock in question. Biogen (BIIB 0.63%) surged higher by more than 38% on Monday, and the gains came on hopes that the company might finally be able to solve the problem of Alzheimer's disease once and for all.

Medical professional wearing mask holding hand of an older patient.

Image source: Getty Images.

An approval for Biogen

Biogen's stock soared after a long trading halt that lasted nearly three hours. At noon EDT, Biogen issued a press release that announced the FDA's accelerated approval of its aducanumab-avwa treatment for Alzheimer's disease. Using the marketing name Aduhelm for the drug, Biogen claimed the status as having the first and only Alzheimer's treatment addressing what it called "a defining pathology of the disease" by reducing amyloid beta plaque levels in patients' brains.

Biogen said that the FDA issued the accelerated approval based on clinical trial data demonstrating plaque reduction. It'll be up to continuing studies to verify that success in fighting amyloid beta plaque will actually reduce the rate of clinical decline that Alzheimer's disease patients suffer.

CEO Michel Vounatsos calling the approval a "historic moment" and celebrated the decade-long work of numerous researchers. Officials at Eisai (ESALY 1.17%), which has worked together with Biogen on the treatment, were similarly pleased. Eisai stock jumped as much as 70% in over-the-counter trading.

Why Biogen's win is controversial

Yet others remain skeptical about Biogen's victory. Although the company has done a good job of showing the direct impact of the treatment on amyloid protein formation, making the further link to demonstrate actual improvement in Alzheimer's symptoms like cognitive ability has been more elusive. In fact, past trials have specifically failed to establish statistically significant benefits.

Also unusual is the extent of disagreement among researchers in the field. A panel of independent experts wasn't convinced when presented with Aduhelm's results that the treatment could directly improve symptoms.

Nevertheless, Biogen can expect sales of Aduhelm to be brisk. With the only approved treatment on the market, Biogen will have many medical professionals looking to try it even if they're skeptical about its eventual impact. That will inevitably produce billions of dollars in revenue for Biogen while allowing the company to continue collecting data on any positive impacts of the treatment on patients.

Hoping for a cure

It's precisely because so much is on the line for so many people that Biogen's Alzheimer's treatment generates such strong emotion. Nevertheless, everyone has to be hoping that Aduhelm will be able to prove itself once and for all and start providing relief for those who suffer from the disease.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$222.38 (0.63%) $1.39
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$33,912.44 (0.45%) $151.39
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,297.14 (0.40%) $16.99
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$13,047.19 (0.00%) $0.00
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
ESALY
$46.56 (1.17%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.